Our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects.
Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint, and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction.
Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.
Leadership Team
Our leaders are experienced drug developers who are committed to transforming the treatment paradigm for patients living with immune-mediated diseases.
Our experienced leadership team brings a proven track record in small-molecule compound drug development for immune-mediated diseases. Our team is poised to deliver on our mission to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
Martin Babler
President, Chief Executive Officer and Chairman of the Board
Martin Babler is the President, Chief Executive Officer and Chairman of the Board at Alumis, Inc. Prior to Alumis, he served as President and CEO of Principia Biopharma, until its acquisition by Sanofi in October 2020. Prior to Principia Biopharma, Martin served as President and CEO of Talima Therapeutics from 2007 to 2011. From 1998 to 2007, he held several positions at Genentech, most notably as Vice President, Immunology Sales and Marketing. While at Genentech, he also helped to build and lead the Commercial Development organization and led the Cardiovascular Marketing organization. Martin previously served at Eli Lilly and Company in positions focused on sales, sales management, global marketing, and business development. Martin serves on the Board of Directors of Prelude Therapeutics Inc., Sardona Therapeutics, 89bio and the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization. Martin received a Swiss Federal Diploma in Pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.
Mark Bradley
Chief Development Officer
Mark Bradley joined in March 2021 as our Chief Development Officer. He brings 30 years of experience in the biotechnology industry. Before joining Alumis he was Senior Vice President (SVP) and South San Francisco Site Head at MyoKardia following that company’s acquisition by Bristol Myers Squibb (BMS), and SVP and Project Team Leader for CAMZYOS® prior to the acquisition. Before MyoKardia, Mark held various roles at Biomarin and Genentech, most recently serving as Head, Business Management, gRED Clinical Operations. Mark began his career at UCSF in public health research and received his B.A. and M.A. from the University of California, Berkeley.
Kolbot By
SVP, Head of Technical Operations
Kolbot By joined in January of 2022 as Senior Vice President of Technical Operations. He has more than 20 years of experience in the biopharmaceutical industry, overseeing manufacturing processes of new chemical entities, and advancing development programs from proof of concept to commercial production. Prior to Alumis, Kolbot was SVP, Technical Operations at Rain Therapeutics where he led the company’s late-stage CMC development program. Prior to Rain Therapeutics, Kolbot was Vice President, Chemical Development at Principia Biopharma where he led the company’s late-stage drug substance program. Prior to Principia Biopharma he was at Corvus Pharmaceuticals, Onyx Pharmaceuticals, Aryx Therapeutics, and NPS Pharmaceuticals. While at Onyx, Kolbot helped to develop the carfilzomib drug substance program from Phase 2 through commercialization. Kolbot holds a B.S. in chemistry from UC Santa Barbara and a Ph.D. in chemistry from UC Davis.
Jörn Drappa M.D., Ph.D.
Chief Medical Officer
Jörn Drappa, MD, Ph.D. joined in August 2022 as our Chief Medical Officer (CMO). He is a board-certified rheumatologist with over 25 years of experience in developing novel treatments for autoimmune and inflammatory diseases. Most recently, he served as CMO at Ventyx Biosciences. Prior to Ventyx Biosciences, Dr. Drappa co-founded Viela Bio, a biotechnology company focused on the discovery, development and commercialization of treatments for autoimmune and severe inflammatory diseases serving as its Head of R&D and CMO until its acquisition by Horizon Therapeutics in March 2021. At Viela Bio, Dr. Drappa led the development of UPLIZNA® (inebilizumab-cdon) in multiple indications, culminating in its approval for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD). Prior to Viela Bio, he held various roles of increasing responsibility leading clinical development programs at MedImmune/AstraZeneca, Genentech, and Amgen. Dr. Drappa received his medical and Ph.D. degrees from the University of Cologne in Germany. He completed a residency in internal medicine at New York Presbyterian Hospital and a fellowship in rheumatology at the Hospital for Special Surgery, NY.
David M Goldstein, Ph.D.
Chief Scientific Officer
David Goldstein, Ph.D. joined in September 2021 as our Chief Scientific Officer (CSO). He is a recognized expert in the fields of small molecule drug discovery, kinase inhibitor design and covalent technologies. David has more than 25 years of industrial experience and has led teams that advanced several small molecule drug candidates into clinical trials in immune-mediated diseases including tolebrutinib, rilzabrutinib, atuzabrutinib and pamapimod. He is a named inventor on more than 40 patents, and he has authored more than 40 scientific publications. Most recently, David was the CSO at Principia Biopharma, a company he helped to launch in 2011 and take public in 2018. Prior to joining Principia, David held positions of increasing responsibility at Roche including Head of Inflammation Chemistry. David serves on the Board member of Frontier Medicines in South San Francisco. He received his Ph.D. in Chemistry at the University of Virginia and completed postdoctoral studies in organic chemistry at the University of Pittsburgh.
Grace Halteh
SVP, Head of Quality and Regulatory
Grace joined in September 2022. She currently serves as Senior Vice President, Head of Quality and Regulatory. She brings over 25 years of experience in life sciences quality & compliance, operations excellence, and project management. As a quality professional, Grace has recognized expertise in quality management & compliance, inspection readiness, vendor management programs, clinical study execution, and due diligence initiatives. She helped lead Global Health Authority inspections, resulting in the successful registration of multiple Biologics and small molecule products. Grace brings strong leadership and end to end vision across various GxP quality functions encompassing establishment of quality management departments, conducting operational assessments, implementing process improvements, and building quality systems. Prior to joining Alumis, Grace was the VP of Quality at Arcellx and a member of the Executive Management team. She held various quality and operations leadership roles at Exelixis, Nektar Therapeutics, Jazz Pharmaceuticals, Genentech, Janssen - A Johnson and Johnson Company, Elan Pharmaceuticals and Syntex. Grace holds an M.S. in Systems Management, and a B.S in Cell and Molecular Biology.
Roy Hardiman
Chief Business Officer
Roy Hardiman joined in September 2021 as our Chief Business Officer. He has over 30 years of business development, legal, alliance management and strategic experience in the biopharmaceutical field. Before joining Alumis, he was Chief Business Officer of Principia Biopharma where he negotiated the company’s core collaborations with Sanofi and AbbVie. Roy spent almost two decades at Genentech where he was one of the company’s lead negotiators, accountable for the alliance and legal aspects of the company’s relationship with Roche. Prior to joining Genentech, Roy was an attorney with Morrison & Foerster LLP. Roy received his B.A. in pharmacology and M.A. in biology (biochemistry/molecular biology emphasis) from University of California, Santa Barbara, and his JD from University of California, Los Angeles School of Law, and serves on the Board of Trustees of the University of California, Santa Barbara Foundation.
Sara Klein
Chief Legal Officer and Corporate Secretary
Sara Klein joined in January of 2022 as our Chief Legal Officer and Corporate Secretary. Before joining Alumis, she was Head of Legal at Principia Biopharma following that company’s acquisition by Sanofi, and Senior Vice President, Legal prior to the acquisition. At Principia Biopharma Sara had general responsibility for the company’s legal, IP and compliance functions, and co-chaired the Operating Committee. Prior to joining Principia Biopharma, Sara was in the private practice of law representing life science and technology companies. She started her career at the law firm of Baker & McKenzie, then was an in-house corporate lawyer at Genentech. Sara graduated from Middlebury College and UC Law SF (formerly UC Hastings).
Claire Langrish
SVP, Head of Immunology and Translational Science
Claire joined in September of 2021. She currently serves as Senior Vice President, Head of Immunology and Translational Science. She is a recognized leader in the field of immunology, with a focus on drug discovery in immune mediated diseases. Claire previously served as Vice President, Head of Immunology and Biology at Principia Biopharma, where she championed target biology, preclinical and clinical translation, building novel insights and deeper understanding of BTK beyond the B cell. Prior to Principia Biopharma, she held positions of increasing responsibility at DNAX, Roche, Takeda and Theravance. During her postdoctoral studies, Claire was credited with the discovery of Th17 cells, and uncovered the key role of IL-23 and IL-17 in autoimmunity, prompting rewritten text-books and a new wave of approved medicines for patients. Claire received a B.S. in Biochemistry from Imperial College London, and a Ph.D. in Immunology from Great Ormond Street Institute of Child Health, University College London, UK.
Derrick Richardson
SVP of People and Culture
Derrick Richardson joined in January of 2022 as Vice President of Program and Portfolio Management. He transitioned into the role of Senior Vice President of People and Culture in June of 2023. He brings over 25 years of experience spanning drug and medical device development. Before joining Alumis he was Head of Cardiovascular Late-Stage Project Management at MyoKardia following that company’s acquisition by Bristol Myers Squibb (BMS) and Executive Director, Project Management prior to the acquisition. During his time at BMS, Derrick’s team was responsible for a portfolio that included CAMZYOS® and ELIQUIS®. At MyoKardia, Derrick led a team that integrated rapidly evolving research, clinical development, BD and commercial functions. Prior to MyoKardia, he worked as a project management and business operations consultant to AbbVie and Genentech. Derrick’s career began in the medical device industry where he made numerous contributions to innovations in laparoscopic surgery, lab automation and cardiovascular implants. He holds a B.S. in Product Design Engineering from Stanford University and a Master of Engineering in Mechanical Engineering from Cornell University.
John Schroer
Chief Financial Officer
John Schroer joined in May 2022 as our Chief Financial Officer (CFO). He brings more than 30 years of biopharmaceutical development and investing experience in the life sciences industry. In his role at Alumis, John is responsible for leading Finance, Corporate Communications, Facilities, and Information Technology. Prior to Alumis, John served as the CFO for ArsenalBio Inc. Previously, John was CFO of Translate Bio (acquired by Sanofi). Earlier in his career, John held Portfolio Manager and Senior Analyst roles managing investment teams and portfolios across the life sciences industry, most recently with Allianz Global Investors. Previously, John was with Schroer Capital, HealthCor Management, ITROS Capital, INVESCO Funds Group and TCW Group. John serves on the board of Azitra. He received his B.S. in History and International Relations from the University of Wisconsin-Madison, and his M.B.A from the University of Wisconsin-Madison School of Business. John is also a CFA® charterholder.
Board of Directors
Martin Babler
President and CEO, Chairman of the Board
Srinivas Akkaraju, M.D., Ph.D.
Founder and Managing Member, Samsara BioCapital
Alan Colowick
Managing Director, AyurMaya, an affiliate of Matrix Capital Management
Patrick Machado, J.D.
Independent Board Member
Sapna Srivastava
Independent Board Member
Jim Tananbaum, M.D.
Founder and CEO, Foresite Capital
Zhengbin (Bing) Yao, Ph.D.
CEO, ArriVent Biopharma